Week In Review: AstraZeneca AB Commits $800 Million To China

December 19, 2015 -- AstraZeneca will invest $800 million in China over ten years to build its build its biologics portfolio, using WuXi AppTech to manufacture biologics and optioning a $100 million facility from WuXi; WuXi Healthcare Ventures II raised $290 million to fund cross-border investments and led a $30 million financing for AltheaDx, a San Diego diagnostics company; Meinian Onehealth upped its bid for iKang Healthcare, a rival chain of China clinics, to $23.50 per ADS; Yisheng Biopharma of Beijing will collaborate with the United States Army Medical Research Institute to develop an Ebola vaccine; Beijing's Novogene partnered with Illumina to develop clinical diagnostics for China prenatal and oncology testing; Easton Pharma of Chengdu and Germany's XL-protein GmbH will develop long-acting ophthalmology treatments; Shanghai's Hutchison MediPharma started a China Phase III trial of cancer drug sulfatinib; and Celsion of New Jersey received CFDA approval to conduct China clinical trials of its liver cancer drug as part of a Phase III global study.

Back to news